Healthcare Industry News: inhaled antibiotic
News Release - August 10, 2007
MAP Pharmaceuticals Promotes Stephen B. Shrewsbury to Position of Chief Medical OfficerMOUNTAIN VIEW, Calif., Aug. 10 (HSMN NewsFeed) -- MAP Pharmaceuticals, Inc. today announced that Stephen B. Shrewsbury, M.B. Ch.B., has been promoted to Chief Medical Officer, a newly created position. Dr. Shrewsbury most recently served as the company's Vice President, Clinical and Regulatory Affairs. He will be the principal medical advisor and head of all medical staff, responsible for overseeing all medical and business components of the clinical development process, strategy and clinical plans to optimize the advancement of the Company's technology, and serving as the Company's medical spokesperson.
"Steve's scientific vision, personal contributions and exceptional leadership have played an instrumental role in moving our pipeline into late-stage development," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "Steve's strong commitment to clinical excellence and developing novel treatments for unmet medical needs, as well as his extensive experience in bringing pharmaceutical brands through the clinical development process to regulatory approval, will be a tremendous asset to the Company as we enter Phase 3 clinical studies."
Dr. Shrewsbury brings more than 25 years of medical expertise with a focus on research, clinical development, medical affairs and drug commercialization, having joined MAP Pharmaceuticals in 2005. Dr. Shrewsbury has led the clinical development programs of the Company's two lead product candidates, Unit Dose Budesonide for the treatment of pediatric asthma, and MAP0004 for the treatment of migraine headache, through Phase 2 clinical studies.
Prior to joining the company, Dr. Shrewsbury served as Senior Director of Clinical Development at Chiron Corporation, working on inhaled antibiotics for cystic fibrosis, bronchiectasis, Acute Exacerbations of Chronic Bronchitis (AECB) and Chiron's in-licensed aerosol cyclosporin for preventing lung transplant rejection. Before Chiron, Dr. Shrewsbury held the positions of Director and Senior Clinical Program Head of Respiratory Clinical Development at GlaxoSmithKline PLC, where he led the inhaled steroid (Flovent HFA) and global Upper Respiratory Inflammatory Disease development programs, as well as contributing to both Advair Diskus and Advair HFA New Drug Application submissions.
Dr. Shrewsbury holds diplomas in Pharmaceutical Medicine from the Royal College of Physician's (UK) Faculty of Pharmaceutical Medicine and the Royal College of Obstetricians and Gynecologists (UK), and holds a medical degree in medicine and surgery from Liverpool University. He is a Fellow of the College of Chest Physicians, Academy of Allergy, Asthma and Immunology, College of Chest Physicians and a Member of the American Headache Society as well as a Fellow of the Faculty of Pharmaceutical Medicine (UK).
About MAP Pharmaceuticals
Located in Mountain View, California, MAP Pharmaceuticals, Inc. uses proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. The Company has several proprietary product candidates in clinical development that address large market opportunities, including the two most advanced product candidates: a proprietary formulation of nebulized budesonide for the potential treatment of children with asthma, and a proprietary formulation of inhaled dihydroergotamine for the potential treatment of migraine. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.
This news release may contain forward-looking statements, including with respect to the progress of the Company's clinical trials. These statements involve risks and uncertainties, including, without limitation, uncertainty of clinical trial results or regulatory approvals or clearances. Actual results may differ materially from the results anticipated in these forward-looking statements. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. Additional information on potential factors that could affect the Company's results and other risks and uncertainties are detailed in its Registration Statement on Form S-1/A, filed with the SEC on July 30, 2007, available at edgar.sec.gov.
Source: MAP Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.